Clinical-stage oncology company Black Diamond Therapeutics Inc. (BDTX) is advancing with growing visibility in biotech circles following a series of clinical and strategic updates tied to its lead candidate, silevertinib (BDTX-1535).
The company recently announced the completion of enrollment for its Phase 2 trial evaluating silevertinib in first-line (1L) patients with non-classical EGFR-mutant non-small cell lung cancer (NSCLC). A total of 43 patients have been enrolled, and data on objective response rate (ORR) and preliminary duration of response (DOR) are expected to be released in the fourth quarter of 2025.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.